title: Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season.
authors.forename: Tobias
authors.initials: T
authors.lastname: Feuchtinger
authors.forename: Holger
authors.initials: H
authors.lastname: Bartz
authors.forename: Andrea
authors.initials: A
authors.lastname: von Berg
authors.forename: Frank
authors.initials: F
authors.lastname: Riedinger
authors.forename: Jens
authors.initials: J
authors.lastname: Brauburger
authors.forename: Stephan
authors.initials: S
authors.lastname: Stenglein
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wahn
authors.forename: Uwe
authors.initials: U
authors.lastname: Schauer
mesh_terms: D000293:Adolescent; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D003713:Dendritic Cells / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D000069444:Omalizumab; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab